Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.77 |
| ▸ | NPC1 | O15118 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | RXRA | P19793 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA4 | P22748 | 1/20 | 0.65 |
| ▸ | CA6 | P23280 | 1/20 | 0.65 |
| ▸ | CA7 | P43166 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11277266 | 0.98 | MRGPRX4 (0.75) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL29375753 | 0.94 | SMPD1 (0.75) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL1029034 | 0.94 | SMPD1 (0.75) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL11271923 | 0.93 | SMPD1 (0.73) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL6586504 | 0.93 | SMPD1 (0.73) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL27881765 | 0.91 | NPC1 (0.77) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL1600077 | 0.91 | MRGPRX4 (0.62) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL29556736 | 0.91 | MRGPRX4 (0.62) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL31025721 | 0.90 | NPC1 (0.75) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL340620 | 0.90 | NPC1 (0.75) | MRGPRX4NPC1RAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4098816-A | HYPOGLYCEMIC AGENTS AND ANTILIPEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1978-07-04 | — | — | US | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-4678637-A1 | NOVEL FLAVONE DERIVATIVE AND USE THEREOF IN ALLEVIATING PULMONARY FIBROSIS | A-chembio Co., Ltd (KR) | 2026-01-14 | — | — | EP | disclosed |
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12496351-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-12433950-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-10-07 | — | — | US | disclosed |
| EP-3580302-B1 | REDOX FLOW BATTERY ELECTROLYTES | CMBLU ENERGY AG (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-3580389-B1 | NOVEL METHODS FOR PROCESSING LIGNOCELLULOSIC MATERIAL | CMBLU ENERGY AG (DE) | 2025-09-17 | — | — | EP | disclosed |
| EP-0635480-B1 | Anthracene derivatives | WAKO PURE CHEM IND LTD (JP) | 1997-03-19 | — | — | EP | disclosed |
| US-5576359-A | ANTHRACENE DERIVATIVE, SOLVENT, COMPOUND CONTAINING GLYCIDYL GROUPS | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1996-11-19 | — | — | US | disclosed |
| EP-0636941-B1 | Deep ultraviolet absorbent and its use in pattern formation | WAKO PURE CHEM IND LTD (JP) | 1996-03-20 | — | — | EP | disclosed |
| US-5498748-A | PHENOLIC CROSSLINKER FOR A POLYGLYCIDYL METHACRYLATE TO FORM A MATERIAL USED AS AN ANTIREFLECTION COATING FOR DEEP UV LIGHT SUCH AS KRF EXIMER LASERS IN SEMICONDUCTOR PHOTORESISTS | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0636941-A1 | Deep ultraviolet absorbent and its use in pattern formation | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1995-02-01 | — | — | EP | disclosed |
| EP-0635480-A1 | Anthracene derivatives | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1995-01-25 | — | — | EP | disclosed |
| EP-0613879-A1 | PHELLODENDRINE ANALOGS AND ALLERGY TYPE IV SUPPRESSOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1994-09-07 | — | — | EP | disclosed |
| EP-0019081-B1 | FLAVONE DERIVATIVES, THEIR PREPARATION, THESE NOVEL AND KNOWN FLAVONES AS ANTIVIRAL AGENTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-10-24 | — | — | EP | disclosed |
| EP-0019081-A1 | Flavone derivatives, their preparation, these novel and known flavones as antiviral agents, and pharmaceutical compositions containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-11-26 | — | — | EP | disclosed |
| US-4098816-A | HYPOGLYCEMIC AGENTS AND ANTILIPEMIC AGENTS | BEECHAM GROUP LIMITED (GB) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD4, CD2, B2M | MRGPRX4 2210/4885NPC1 4204/4885RAB9A 4485/4885 |
| US-12433950-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | MRGPRX4 3518/4885NPC1 3147/4885RAB9A 3843/4885 |
| US-12496351-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | MRGPRX4 3518/4885NPC1 3147/4885RAB9A 3843/4885 |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | MRGPRX4 3518/4885NPC1 3147/4885RAB9A 3843/4885 |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | MRGPRX4 4104/4885NPC1 4195/4885RAB9A 4030/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | MRGPRX4 1535/4885NPC1 1370/4885RAB9A 3107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.